<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mann, Kate</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Novel Once-Weekly Omarigliptin as Effective and Well Tolerated as Once-Daily Sitagliptin in Japanese Patients</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">26-27</style></pages><abstract><style  face="normal" font="default" size="100%">Patient adherence to glucose-lowering medications is a major challenge in type 2 diabetes mellitus. It is thought that an effective, well-tolerated, weekly oral antihyperglycemic agent could provide better glycemic control due to increased adherence. This article examines results of the MK-3102 Phase III Clinical Trial [NCT01703221], which evaluated the safety and efficacy of the novel dipeptidyl peptidase-4 inhibitor omarigliptin compared with placebo and sitagliptin in Japanese patients with type 2 diabetes mellitus.</style></abstract><number><style face="normal" font="default" size="100%">32</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>